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Probing the Dependence of pH on Sugar Binding and Protein Structure in
a Polysaccharide Lyase
Sook Wong, Jeffery B. Klauda.
Chemical and Biomolecular Engineering, University of Maryland, College
Park, MD, USA.
Polysaccharide lyases (PLs) are enzymes that our commonly used by microor-
ganisms to degrade polyuronides. These enzymes are produced by bacteria to
aid in reducing the high molecular weight of the host’s extracellular matrix
to enhance its virulence. PLs can also be used to degrade polysaccharides as
a source of carbon for the pathogen. Our focus is on the alginate lyase of Sten-
otrophomonas maltophilia (Smlt1473), which has been shown recently to be
active against alginate, hyaluronic acid (HA) and poly-D-glucuronic acid at
varying pH values (J. Biol. Chem. 289: 312 (2014)). The active site appears
to have regions specific to binding these three sugars and an active catalytic
site. Our objective is to understand how pH influences binding of a HA and
if this involves structural changes in the protein. Docking of HA to a
homology-based structure of Smlt1473 (based on the crystal structure of algi-
nate lyase A1-III) was used to provide initial starting conformations for our
molecular dynamics (MD) simulations. ProPKa was used to determine the ioni-
zation state of residues at our three simulated pHs (5, 7 and 9). MD simulations
at neutral pH confirm the binding residues seen in experiment. However, at the
acidic and basic condtions, the homology-based model of the binding pocket
opens. At ph¼5, there is an increase in the exposure of HA-specific residues
in the vicinity of W171 suggesting this exposure is the cause for Smlt1473
increased activity (J. Biol. Chem. 289: 312 (2014)). Therefore, Smlt1473’s
structure appears to strongly depend on pH and is used to control its activity
toward different sugars.
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Probing the Role of Conformational Entropy in Protein-Inhibitor Binding
Kyle Harpole1, Senthil Kumar Ganesan2, Wolfgang Peti2, A. Joshua Wand1.
1Department of Biochemistry and Biophysics, University of Pennsylvania
Perelman School of Medicine, Philadelphia, PA, USA, 2Department of
Molecular Pharmacology, Physiology and Biotechnology, Brown University,
Providence, RI, USA.
In silico drug discovery has long held the promise to revolutionize the way
drugs are designed, but has largely failed to deliver. Historically inhibitors
were designed based mainly on static structures that emphasized interaction
energetics but ignored potential contributions from conformational entropy.
This issue has been difficult to address experimentally. Recently, we have
developed an NMR-based approach that employs measures of motion as a
proxy for the conformational entropy. Using an empirical calibration, we
have shown that the resulting ‘‘entropy meter’’ is both robust and general.
We hypothesize that conformational entropy represents a critical ‘‘missing
piece’’ in rational drug design. Using the ‘‘entropy meter,’’ we examine the
effect of conformational entropy on protein-inhibitor interactions using the
drug target and mitogen-activated protein kinase (MAPK) p38a as a model sys-
tem. Given the relatively large size of this protein, all studies were performed in
a perdeuterated background. Using standard methods, we have obtained nearly
complete ILV methyl assignments of this protein. 15N and 13C NMR spin
relaxation experiments were used to determine the sub-ns dynamics of the
protein both in the apo state and bound to either a competitive and a non-
competitive (allosteric) inhibitor. In both cases, we observe the a large unfavor-
able entropic effect of binding. We find that the conformational entropy change
upon binding represents a significant contribution to the overall binding free en-
ergy. These results promote further studies to understand how classes of inhib-
itors may modulate the dynamics and corresponding internal entropy of protein
targets, and how this information can be used to design better lead compounds.
This work was supported by NIH Grant GM100910
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Ligand Discovery for the Alanine-Serine-Cysteine Transporter (ASCT2,
SLC1A5) from Homology Modeling and Virtual Screening
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The Alanine-Serine-Cysteine transporter ASCT2 (SLC1A5) is a membrane pro-
tein thatmoves neutral amino acids into cells in exchange for outwardmovementof intracellular amino acid. ASCT2 is highly expressed in peripheral tissues such
as the lung, kidney, intestines, and testis where it contributes to the homeostasis
of intracellular concentrations of neutral amino acids. ASCT2 also plays an
important role in the development of a variety of cancers such as melanoma,
by transporting amino acid nutrients such as glutamine into the proliferating tu-
mors. Therefore,ASCT2 is a key drug targetwith potentially great pharmacolog-
ical importance. Here, we identify seven ASCT2 ligands by computational
modeling and experimental testing. In particular,we construct homologymodels
based on crystallographic structures of the aspartate transporter GltPh in two
different conformations, and optimize the models’ binding sites for protein-
ligand complementarity. Virtual screening of 594,166 compounds including
drugs, metabolites, and fragment-like molecules from the ZINC database, fol-
lowed by experimental testing of 11 top hits with functionalmeasurements using
electrophysiologicalmethods reveals seven ligands including five activators and
two inhibitors. For example, aminooxetane-3-carboxylate is a more efficient
activator than any other known ASCT2 natural or unnatural substrate. Further-
more, two of the hits inhibited ASCT2 mediated glutamine uptake and prolifer-
ation of a melanoma cancer cell line. Our results improve our understanding on
how substrate specificity is determined in amino acid transporters as well as
provide novel scaffolds for developing drugs targeting ASCT2, an emerging
therapeutic target for cancer and neurological disorders.
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Thermodynamic Properties of ELP-Labelled Doxorubicin, a Drug
Delivery System
Valeria Zai-Rose.
Biochemistry, University of Mississippi Medical Center, Jackson, MS, USA.
Macromolecular delivery by hyperthermia and thermal targeting of SynB1-Cys
ELP-bound Doxorubicin (Dox) to solid tumors is investigated in animal studies
as a means of circumventing multidrug resistance in cancer cells. The structural
changes and hydrodynamic properties of ELP below and above its Transition
Temperature TT make this construct a useful carrier for the delivery of Dox.
At low temperature, the ELPs are soluble and consist of both random coils
and b-turn structures. With increasing temperature ELPs undergo weak associ-
ation, forming repeating type II b-turns and b-spirals. Above the TT, they un-
dergo a cooperative phase transition involving mm size aggregates stabilized by
desolvation. Sedimentation velocity (SV) experiments have shown that ELP is
a nonideal monomer at low temperature, but with increase in temperature un-
dergoes weak isodesmic self-association. Adding Cell Penetrating Peptides
(SynB1) at the N-terminal domain of the ELP decreases its solubility and sta-
bilizes the aggregated state. This study asks how the addition of Dox to SynB1-
Cys ELP affects its biophysical and hydrodynamic behavior at physiological
conditions, and how these changes influence its potential for aggregation and
drug delivery. The preliminary SV results presented here show an increase in
self-association of SynB1-Cys ELP-Dox at 20C relative to the unlabeled
construct. The goal of these experiments is to investigate the impact of different
labeling efficiencies (10-90%) on self-association and TT. Preliminary
turbidity results on unlabeled SynB1-Cys ELP in PBS show that TT decreases
linearly with increase in the logarithm of the ELP concentration as solutions are
heated from 20 to 60C. The process is reversible as solutions are cooled to
20C. The degree of conformational change associated with the TT will also
be monitored using CD and FT-IR experiments.
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Understanding the Function of a Pro-Angiogenic Polypeptide hFGF-1 with
a Cancer Inhibitor Imatinib
Tulsi Modi, Oluwadamilola Filani, Jason Payne, Raja Murthy.
Chemistry, Western Kentucky University, Bowling Green, KY, USA.
Fibroblast growth factors (FGFs) lack signal sequences, and are exported
through endoplasmic reticulum (ER)-Golgi-independent non-classical routes.
FGFs work as modulators of various cellular activities like mitosis, differenti-
ation, survival etc. Among the FGF family, which comprises of 23 different
heparin proteins, human FGF-1 (hFGF-1), a potent angiogenic factors are
one of the targets in cancer inhibition, as they are involved in blood vessel for-
mation in tissues. There has been intensive research directed at the develop-
ment of drugs that could effectively inhibit angiogenesis. In this context, the
purpose of this study is to fully understand the molecular principles essential
to determine probability of inhibition of hFGF-1 signaling transduction by im-
atinib. Imatinib, a 2-phenyl amino pyrimidine derivative is a tyrosine kinase in-
hibitor with antineoplastic activity. Imatinib binds to the intracellular pocket
located within tyrosine kinases and inhibit the downstream cell proliferation
events, but the exact molecular mechanism is still elusive. In this study, expres-
sion of hFGF-1 in recombinant E.coliwas carried out, and the expressed protein
was purified using heparin affinity column chromatography. The structural in-
teractions governing imatinib-hFGF-1 interaction was studied by monitoring its
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steady state fluorescence and proteolytic digestion assay. These data show
that imatinib binds to hFGF-1 and enhances its thermal stability and solvent
accessibility. In addition, Biacore analysis was carried out to determine the
binding affinity of imatinib to hFGF-1. 1H-15N HSQC NMR was also per-
formed in order to determine exact binding sites and stoichiometry of binding
between imatinib and hFGF-1.
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The intravenous general anesthetics propofol and thiopental target pentameric
ligand-gated ion channels (pLGIC) and inhibit cation-conducting nAChRs.
These drugs also inhibit ELIC, a prokaryotic pLGIC. However, the binding
sites for these anesthetics are unknown for either nAChRs or ELIC. Here, using
photoaffinity labeling, two-electrode voltage clamp electrophysiology and mo-
lecular docking, we identified a functionally relevant binding site for thiopental
and propofol in ELIC. Molecular docking identified two binding pockets: an
intrasubunit site near M265 of TM3, partially overlapped with the previously
identified propofol binding site in GLIC; and an intersubunit site near W220
of TM1, which overlaps with the bromoform binding location identified previ-
ously. We generated two mutants, one targeted both predicted binding sites
(W220F/W224F/M265C) and another targeted only the intrasubunit site
(M265C). Functional measurements on Xenopus oocytes expressing the
W220F/W224F/M265C mutant show a significant decrease of anesthetic inhi-
bition, with a five-fold increase in the propofol IC50 and abolishment of thio-
pental inhibition. Interestingly, the M265C mutation alone could produce the
same effect as the W220F/W224F/M265C mutant. Photoaffinity labeling ex-
periments with a light-activated derivative of propofol (aziPm), in conjunction
with mass spectrometry, confirmed the binding site at M265 for aziPm. Alto-
gether, the results show that propofol and thiopental bind to a common func-
tionally relevant site. This intrasubunit action site may also be shared by
other intravenous anesthetics. Research supported by grants from the NIH.
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Crystal View of Anesthetics and Alcohols Bound in the Pore of ELIC
Qiang Chen1, Monica N. Kinde1, Aina E. Cohen2, Pei Tang1, Yan Xu1.
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Cys-loop receptors, including the acetylcholine, glycine, 5-HT3 and GABA re-
ceptors, are molecular targets of general anesthetics and alcohols. Molecular
mechanisms of anesthetics and alcohols interacting with Cys-loop receptors
are still unclear. ELIC is a prokaryotic homolog of Cys-loop receptors and
can be inhibited by general anesthetics and alcohols. Here, we report crystal
structures (~3.1 A˚) of ELIC bound with the volatile general anesthetic isoflur-
ane, and bound with 2-bromoethanol. The crystal structures were obtained in
the presence and absence of the agonist propylamine. Isoflurane was found in-
side the pore at two sites near T237(60) and A244(130), respectively, but 2-bro-
moethanol was only found near T237(60). In addition, 2-bromoethanol also
bound near Y102 and E150 in the extracellular domain. The presence of propyl-
amine had no obvious effect on the binding sites for both isoflurane and 2-bro-
moethanol. This is the first time that an anesthetic or alcohol has been observed
in the pore at an atomic resolution. The newly identified binding sites of isoflur-
ane and 2-bromoethanol in ELIC are significantly different from previously re-
ported anesthetic and alcohol binding sites. Neither isoflurane binding nor
2-bromoethanol binding introduced significant structural perturbation. The
binding of isoflurane and 2-bromoethanol inside the pore suggests the possibil-
ity of channel occlusion as a mechanism for channel inhibition of Cys-loop re-
ceptors by general anesthetics and alcohols. Supported by grants from NIH.
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Siobhan M. Deis1, Charles E. Dann III2.
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Antifolates, analogues of the essential vitamin folic acid, are used in the clinic
to treat cancers and inflammatory diseases. Antifolates are primarily trans-
ported into cells via the endogenously expressed reduced folate carrier
(RFC). Conversely, our collaborators in Aleem Gangjee’s group at DuquesneUniversity have synthesized antifolates (AG antifolates) that transport poorly
by the RFC, but are efficiently transported by the folate receptor (hFR). The
GPI-anchored hFR is lowly expressed on the apical surface in a subset of
normal epithelial lineages, but is highly expressed in many cancers of epithelial
origin and on activated macrophages in inflammatory disease. Therefore, AG
antifolate molecules have specificity for transport into disease cells over
healthy cells. These newly developed AG antifolates cause cell death via inhi-
bition of an enzyme involved in de novo purine synthesis, glycinamide ribonu-
cleotide (GAR) transformylase.
We analyzed a series of AG antifolates using biophysical and biochemical tech-
niques to understand both the specificity for transport by the folate receptor as
well as the inhibition of the GAR transformylase in order to drive informed,
hypothesis-based drug design. Our data, including pH-dependent binding pro-
files, enzyme inhibition data, and crystallographic models of protein in com-
plex with AG molecules will be presented in the context of drug design and
development.
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PKA-Dependent Potentiation Mechanisms of Human CFTR Activity
Guangyu Wang.
University of California Davis, Davis, CA, USA.
Both curcumin and VX-770 potentiate the channel activity of human CFTR
(hCFTR) and two most common cystic fibrosis (CF) mutants G551D and
F508delta in an ATP-independent but PKA-dependent manner. The underlying
molecular mechanisms are unclear. Herein, HEK-293T cells cultured in a Fe3þ-
containingmediumwere transiently transfectedwith hCFTR constructs and cur-
cumin with well-known chemical nature was employed as a template to explore
PKA-dependent potentiation mechanisms of hCFTR activity. The results
showed that curcumin potentiation of Fe3þ-sensitive hCFTR activity was
partially weakened by Fe3þ-insensitive mutations at the interface of the R
domain and intracellular loop (ICL) 3 and completely suppressed by sufficient
Fe3þ. Thus, release of the inhibitory Fe3þ-bound R domain from ICL3 by cur-
cumin may be critical for curcumin potentiation. Further study indicated that
curcumin potentiation was significantly prohibited by a missense alanine muta-
tion of F157,Y161 orK166 from ICL1, or R1066, F1074 or F1078 from ICL4, or
S795 or S813 from the R domain with or without the involvement of nucleotide-
binding domain 2 (NBD2). More importantly, curcumin potentiation was also
suppressed by the R811A/S813D or Y808A/S813D mutation and disulfide
crosslinking of K162C to S795C enhanced channel opening. Therefore, the
phosphorylated R domain may function as a length- and gating-regulatory
cross-linker between two transmembrane domains (TMD1 and TMD2). Curcu-
min may potentiate hCFTR activity by stabilizing the stimulatory ICL1/ICL4-R
interactions that promote channel opening by pulling all ICLs together and thus
triggering a gating inward-to-outward reorientation of TMDs. Possible chemical
interactions may involve cation-p interactions, p-p interactions and hydrogen
bonding. Taken together, both release of the R domain from ICL3 and the stim-
ulatory R-ICL1/ICL4 interactionsmay be necessary for PKA-dependent hCFTR
activation and potentiation. These findings may help optimize the potentiators
for treating those CF mutants with an ATP-dependent gating defect.
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Kinase Structural Dynamics Enables Tight and Selective Binding of
Inhibitors
Roman V. Agafonov, Chris Wilson, Vanessa Buosi, Renee Otten,
Dorothee Kern.
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Protein kinases are obvious drug targets against cancer due to their central role
in cellular regulation. With oncologic diseases being the second leading cause
of death in the US kinases rapidly gain attention and are likely to become the
number one drug target. Using NMR and fast kinetics, we establish a novel
model that solves a longstanding question of high selectivity of clinically rele-
vant drug Gleevec that effectively inhibits Abl tyrosine kinase while closely
related Src family of kinases is affected much less. Our study of an entirely
different family of Ser/Thr Aurora kinases and its specific inhibitors suggests
that an energy landscape that provides tight affinity via an induced-fit and bind-
ing plasticity via a conformational selection mechanism is likely to be general
for many inhibitors.
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Plasmodium falciparum is the cause of human malaria and is one of two ma-
laria parasites known to have drug resistance. Since there are no preventative
